Benign Growth For Golden Sun Health Technology Group Limited (NASDAQ:GSUN) Underpins Its Share Price

When close to half the companies operating in the Consumer Services industry in the United States have price-to-sales ratios (or “P/S”) above 1.6x, you may consider Golden Sun Health Technology Group Limited (NASDAQ:GSUN) as an attractive investment with its 0.6x P/S ratio. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the reduced P/S.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

See our latest analysis for Golden Sun Health Technology Group

How Has Golden Sun Health Technology Group Performed Recently?

Golden Sun Health Technology Group certainly has been doing a great job lately as it’s been growing its revenue at a really rapid pace. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the P/S ratio. Those who are bullish on Golden Sun Health Technology Group will be hoping that this isn’t the case, so that they can pick up the stock at a lower valuation.

We don’t have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Golden Sun Health Technology Group’s earnings, revenue and cash flow.

How Is Golden Sun Health Technology Group’s Revenue Growth Trending?

There’s an inherent assumption that a company should underperform the industry for P/S ratios like Golden Sun Health Technology Group’s to be considered reasonable.

If we review the last year of revenue growth, the company posted a terrific increase of 65%. Despite this strong recent growth, it’s still struggling to catch up as its three-year revenue frustratingly shrank by 32% overall. Therefore, it’s fair to say the revenue growth recently has been undesirable for the company.

Weighing that medium-term revenue trajectory against the broader industry’s one-year forecast for expansion of 13% shows it’s an unpleasant look.

With this information, we are not surprised that Golden Sun Health Technology Group is trading at a P/S lower than the industry. However, we think shrinking revenues are unlikely to lead to a stable P/S over the longer term, which could set up shareholders for future disappointment. Even just maintaining these prices could be difficult to achieve as recent revenue trends are already weighing down the shares.

The Final Word

It’s argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

As we suspected, our examination of Golden Sun Health Technology Group revealed its shrinking revenue over the medium-term is contributing to its low P/S, given the industry is set to grow. At this stage investors feel the potential for an improvement in revenue isn’t great enough to justify a higher P/S ratio. If recent medium-term revenue trends continue, it’s hard to see the share price moving strongly in either direction in the near future under these circumstances.

You always need to take note of risks, for example – Golden Sun Health Technology Group has 2 warning signs we think you should be aware of.

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.